Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix

被引:0
作者
Halmos, G
Schally, AV
Kahan, Z
机构
[1] Vet Adm Med Ctr, Inst Endocrine Polypeptide & Canc, New Orleans, LA 70112 USA
[2] Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA
关键词
LH-RH receptors; ovarian cancer; subcellular localization of receptors;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The inhibition of growth of various hormone-dependent cancers by analogs of luteinizing hormone-releasing hormone (LH-RH) may be exerted in port through receptors for LH-RN present on tumor cells, but the direct mode of action of LH-RH agonists and antagonists is still not completely understood. The aim of this study was to investigate the effects of agonist [D-Trp(6)]LH-RH and antagonist Cetrorelix, administered s.c, at a dose of 100 mu g/day for 3 weeks on the binding characteristics and subcellular localization of receptors for LH-RH in OV-1063 human epithelial ovarian cancers xenografted into nude mice. Using radioligand binding studies, following in vitro desaturation, we demonstrated the presence of specific, high affinity binding sites for LH-RH in both cell membrane and nuclear fraction of OV-1063 tumors. Treatment with Cetrorelix, but not [D-Trp(6)]LH-RH, caused about 60% reduction (p<0.01) in tumor volume and weight. [D-Trp(6)]LH-RH decreased the number of LH-RN receptors on OV-1063 tumor membranes by 44% after 14 days (p<0.01), and the concentration of receptors remained at that level on day 21. The maximal binding capacity of receptors for LH-RH in the nuclei was significantly higher (p<0.05) after 3 weeks of treatment with [D-Trp(6)]LH-RH, Cetrorelix decreased the concentration of membrane receptors for LH-RH by 53% (p<0.01) after 14 days and the levels on day 21 were even lower, showing a 70% reduction (p<0.01). In contrast, the number of LH-RN binding sites in the nuclear pellet was significantly increased (p<0.01) by Cetrorelix at that time. Our results demonstrate for the first time that the down-regulation of LH-RN receptors on the cell membranes of OV-1063 human ovarian cancers after therapy with antagonist Cetrorelix or agonist [D-Trp(6)]LH-RH is associated with an increase in receptor concentration in the nuclei. These phenomena could be related to the internalization and subcellular translocation of receptors in these tumor cells.
引用
收藏
页码:367 / 373
页数:7
相关论文
共 32 条
[1]  
Arencibia JM, 2000, INT J ONCOL, V16, P1009
[2]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[3]  
DONDI D, 1994, CANCER RES, V54, P4091
[4]  
Emons G, 1996, CANCER, V78, P1452
[5]   THE USE OF LUTEINIZING-HORMONE-RELEASING HORMONE AGONISTS AND ANTAGONISTS IN GYNECOLOGICAL CANCERS [J].
EMONS, G ;
SCHALLY, AV .
HUMAN REPRODUCTION, 1994, 9 (07) :1364-1379
[6]   Effects of LHRH-analogues on mitogenic signal transduction in cancer cells [J].
Emons, G ;
Müller, V ;
Ortmann, O ;
Schulz, KD .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1998, 65 (1-6) :199-206
[7]  
EMONS G, 1993, CANCER RES, V53, P5439
[8]   Growth-inhibitory actions of analogues of luteinizing hormone releasing hormone on tumor cells [J].
Emons, G ;
Ortmann, O ;
Schulz, KD ;
Schally, AV .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1997, 8 (09) :355-362
[9]   CHARACTERISTICS AND DISTRIBUTION OF RECEPTORS FOR [D-TRP6]-LUTEINIZING HORMONE-RELEASING HORMONE, SOMATOSTATIN, EPIDERMAL GROWTH-FACTOR, AND SEX STEROIDS IN 500 BIOPSY SAMPLES OF HUMAN-BREAST CANCER [J].
FEKETE, M ;
WITTLIFF, JL ;
SCHALLY, AV .
JOURNAL OF CLINICAL LABORATORY ANALYSIS, 1989, 3 (03) :137-147
[10]   Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix [J].
Halmos, G ;
Schally, AV ;
Pinski, J ;
VadilloBuenfil, M ;
Groot, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (06) :2398-2402